3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
985
Leukemia
733
Leukemia, Lymphocytic, Chronic, B-Cell
665
Precursor Cell Lymphoblastic Leukemia-Lymphoma
605
Myelodysplastic Syndromes
502
Lymphoma
340
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
308
Lymphoma, Non-Hodgkin
294
Hematologic Neoplasms
257
Lymphoma, Follicular
223
Multiple Myeloma
213
Burkitt Lymphoma
209
Hodgkin Disease
198
Lymphoma, Large B-Cell, Diffuse
194
Lymphoma, Mantle-Cell
193
Lymphoma, B-Cell, Marginal Zone
189
Leukemia, Myelomonocytic, Chronic
181
Leukemia, Myeloid, Chronic-Phase
171
Recurrence
167
Myeloproliferative Disorders
165
Congenital Abnormalities
140
Lymphoma, Large-Cell, Immunoblastic
132
Leukemia, Myeloid, Accelerated Phase
118
Blast Crisis
115
Anemia, Refractory, with Excess of Blasts
114
Waldenstrom Macroglobulinemia
103
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
102
Primary Myelofibrosis
94
Graft vs Host Disease
88
Neoplasms, Plasma Cell
84
Interventions
ogalvibart
1
crexavibart
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Purpura, Thrombotic Thrombocytopenic
×
Other hematologic neoplasm
×
Clear all
NCT05393999
2023-04-24
SABRE
Imperial College Healthcare NHS Trust
Phase 2
Withdrawn